Matthew T. Wiley, Chief Commercial Officer at Definium Therapeutics, Inc. (DFTX), sold 2,867 shares at $45.03 ($129K) on 2026-06-25, disclosed to the SEC on 2026-06-26.
Scheduled sale ($129k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| BTAI | SELL | 2024-06-18 | $307 | — | Filing → |
| BTAI | SELL | 2024-04-08 | $3K | — | Filing → |
| FOMX | BUY | 2019-03-06 | $101K | — | Filing → |